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Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease accounting for 1% of UK deaths. In the familial form of pulmonary 
fibrosis, causal genes have been identified in ~30% of cases, and a majority relate to telomere maintenance. Prematurely 
shortened leukocyte telomere length associates with IPF, and also chronic obstructive pulmonary disease (COPD), a disease 
with similar demographics and shared risk factors. Using Mendelian randomisation (MR), we investigated evidence supporting 
a causal role for short telomeres in IPF and COPD. 
 
Methods 
MR inference of telomere length causality was performed for IPF (up to 1,369 cases) and COPD (13,538 cases) against 435,866 
controls of European ancestry in UK Biobank. Polygenic risk scores, followed by two-sample MR analyses were carried out using 
seven genetic variants previously associated with telomere length, with replication analysis in an IPF cohort (2,668 cases vs 
8,591 controls) and COPD cohort (15,256 cases vs 47,936 controls). 
 
Findings 
In the UK Biobank, a genetically instrumented one standard deviation shorter telomere length was associated with higher odds 
of IPF (OR=4.19;  95% CI 2.33-7.55, P=0.0031) but not COPD (OR = 1.07; 95% CI 0.88-1.30, P = 0.51). Similarly, an association 
was found in the IPF replication cohort (OR = 12.3; 95% CI: 5.05-30.1, P = 0.015) and not in the COPD replication cohort (OR = 
1.04; 95% CI 0.71-1.53, P = 0.83). Meta-analysis of the two-sample MR results provided evidence inferring that shorter 
telomeres cause IPF (5.81 higher odds of IPF; 95% CI 3.56-9.50; P=2.19x10-12). There was no evidence to infer that telomere 
length caused COPD (OR=1.07; 95% CI 0.90-1.27, P=0.46). 
 
Interpretation 
Cellular senescence is hypothesised as a major driving force in IPF and COPD; telomere shortening may be a contributory factor 
in IPF, suggesting divergent mechanisms in COPD. This enables greater focus in telomere-related diagnostics, treatments and 
the search for a cure in IPF. Therapies manifesting improvements in telomere length warrant investigation. 
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Idiopathic pulmonary fibrosis (IPF) is a complex and incurable fibrotic lung disease. Based on data from 2012 1, the average 
lifespan following diagnosis is widely quoted as being around 3yrs and IPF accounts for around 5300 UK deaths each year, over 
1% of all UK deaths. 
 
 
The association of PF and COPD with telomere length 
In approximately 20% of cases, pulmonary fibrosis (PF) clusters in family groups 2. Inherited genetic causes have been 
established for around 30% of familial cases and the majority relate to telomere maintenance. The most common of these is 
the gene encoding telomerase reverse transcriptase (TERT), a catalytic subunit of the enzyme telomerase which works in 
conjunction with the telomerase RNA component, TERC 3. Variants in these two genes account for 19% of familial cases via 
autosomal dominant inheritance with reduced penetrance.  
Idiopathic pulmonary fibrosis (IPF) risk also has a strong genetic component 4. Prematurely shortened leukocyte telomere length 
(LTL) has been associated with IPF and also chronic obstructive pulmonary disease (COPD), a condition with a similar 
Research in context 
Evidence before this study 
We searched in PubMed for publications up to 25th June 2020 on this subject using the search terms “telomere length”, 
”Mendelian random*” and “pulmonary fibrosis” or ”interstitial lung disease”.  We found a 2017 study which reports 
reduced risk of interstitial lung diseases associated with long telomeres (and no association for COPD) as part of a wider 
Mendelian Randomisation study on the association between telomere length and risk of cancer and non-neoplastic 
diseases. We found no further evidence for the use of MR to investigate causality in IPF. We searched in PubMed up to 
10th June 2019 for GWAS results of SNPs associated with telomere length in order to create the instrument used in our 
MR analysis. We summarise the available evidence of association between telomere length and pulmonary fibrosis in 
animal models and in humans from publications up to this date. 
Added value of this study 
This study builds significantly on previous reports of a likely causal link between telomere length and IPF but not COPD by 
providing comprehensive evidence suggesting causality in IPF using large datasets from UK Biobank plus clinically well-
defined replication cohorts; the study includes direct comparisons of underlying demographic features and draws on data 
from larger cohorts than have been used previously (1,133 IPFs in UKB; 2,668 IPFs in replication cohort; 11,413 COPDs in 
UKB; 15,256 COPDs in replication cohort).  
Considerable experimental effort has been invested into finding a cause of PF in mouse models but there is no 
experimental evidence of causality in humans. This research therefore advances understanding in the fields of IPF and 
COPD research. 
Implications of all the available evidence 
Evidence inferring a cause for IPF allows research into more effective treatments to be pursued with renewed direction. 
It also allows clinicians to propose and patients to undertake known telomere maintenance therapies, which are also 
beneficial to general health. 
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demographic. Studies have shown age adjusted LTL values of 0.85 ± 0.60 vs 1.15 ± 0.6, p=0.0001 relative to reference DNA for 
IPF versus controls 5 and 0.68 ± 0.25 vs. 0.88 ± 0.52, p = 0.003 for COPD versus smoking controls 6. There is also evidence for an 
association between shorter LTL and worsened survival in IPF 7, with the suggestion that LTL could be used as a predictive 
biomarker.  A recent study which included 32 IPF patients undergoing diagnostic lung biopsy demonstrated shortened lung 
telomeres (particularly in type II alveolar epithelial cells within fibrotic lesions), but no correlation with age; half of these showed 
excessive lung telomere shortening, to the same extent seen in PF patients with a TERT mutation – suggestive of a disease 
driven by telomere attrition 8. 
The most widely used model for experimental exploration and pre-clinical assessment for IPF is the murine model of bleomycin-
induced lung injury9. Although this mouse model has been an important precursor to clinical trials and has helped enable the 
development and licensing of the two main IPF treatments, Nintedanib and Pirfenidone, the majority of studies utilise young 
mice where the fibrotic lesions lack features which are characteristic of IPF (such as honeycombing and fibrotic foci), and where 
the fibrosis may resolve depending on the severity of initial injury 10. Mice have particularly long telomeres; studies which have 
utilised aged mice (>18mo old) have demonstrated a more profound fibrotic response which does not resolve 11, and which 
better reflects the human disease. Notably, a recent study of low-dose bleomycin in TERT-/- mice (which have significantly 
shortened telomeres) demonstrated that targeted telomerase activation in type II alveolar epithelial cells (AEC2s) cells using 
gene therapy with adeno-associated vectors (AAV) showed therapeutic effects in mice with established fibrosis 12 through 
telomere elongation and increased proliferation of AEC2 cells combined with lower DNA damage, apoptosis and senescence 
burden. 
Thus, while there is evidence of an association with shorter telomeres in both diseases, experimentally, there is currently only 
evidence from murine models of PF that telomere extension is therapeutic.   
 
Mendelian Randomisation 
A genetic technique known as Mendelian randomisation (MR) 13 can be used to test for inference of a causal relationship 
between a phenotype that can be genetically influenced (such as telomere length) and a disease outcome, such as IPF or COPD. 
Causality in one direction is inferred because genetic make-up is allocated at conception and unlikely to be influenced by disease 
in later life. Potential confounding influences such as smoking, pollution and other environmental/lifestyle risk factors are 
removed from the analysis, creating in effect a natural blind randomised control trial (Figure 1). Recent genome-wide 
association studies (GWAS) 14,15 have identified several genetic variants or single nucleotide polymorphisms (SNPs) that are 
independently associated with telomere length and provide potential tools for MR. A previous study investigating associations 
between genetically increased telomere length and risk of cancer and other non-neoplastic diseases, reported increased risk of 
site-specific cancers and reduced risk of coronary artery disease, celiac disease and interstitial lung diseases 16. We therefore 
hypothesised that telomere length is causally linked to IPF but not COPD, given that inherited genetic defects in telomerase 
production lead to familial pulmonary fibrosis. To test this, we used MR and the latest data release from up to 451,025 
participants in the UK Biobank together with a genetic instrument associated with shorter telomere length. We further tested 






Collection and selection of UK Biobank Data 
The UK Biobank is a study of 500,000 volunteers aged between 37-73 years, recruited across the UK during 2006-2010 17, with 
participant data including physical measurements, biological samples (blood, urine and saliva) for biomarker and genetic 
analysis, and long-term follow-up via hospital record linkage. Information on patient and public involvement is available online 
18. No further ethical or IRB approval was required. The cut-off date for data in this study was 31/3/2017. Genetic variant or 
single nucleotide polymorphism (SNP) data was generated from the Affymetrix Axiom UK Biobank array (for ~450,000 
individuals) and the UK BiLEVE array (~50,000 individuals) following extensive quality control, as described previously 19. 
Individuals were defined as European descent using principal component analysis (PCA). Briefly, principal components were 
generated using loadings from high-confidence SNPs in the 1000 Genomes Cohort. The loadings were then used to project all 
of the UK Biobank samples into the same principal component space, and individuals were then clustered using the first four 
principal components. We identified two UK Biobank study populations: 1) The full set of available participants (451,025 
individuals of European ancestry), including related individuals, to maximise statistical power in the 2-sample Mendelian 
randomisation where relatedness is handled within the model; 2) A smaller subset of 379,708 unrelated individuals (defined 
using a KING Kinship, generating an optimal list of unrelated individuals with maximum inclusion), important for the initial 
regression modelling. Ancestral principal components were then generated within these identified individuals for use in 
subsequent analyses, as described previously 20. 
 
IPF cases within UK Biobank were defined as those having a primary or secondary ICD10 code HES (Hospital Episodes Statistics) 
diagnosis of J84.1. With this ‘narrow’ criterion, we identified 1369 cases (1133 unrelated, whereby no two participants are third 
degree related or closer). We repeated our analysis with a ‘broad’ IPF definition that included J84.0 (Alveolar and parieto-
alveolar conditions), J84.8 (Other specified interstitial pulmonary diseases) or J84.9 (Interstitial pulmonary disease, unspecified) 
and using these criteria, we identified 1,621 (1,353 unrelated) cases. COPD cases were defined as those having a primary or 
secondary ICD10 code of J41 (Simple and mucopurulent chronic bronchitis), J42 (Unspecified chronic bronchitis), J43 
(Emphysema) or J44 (Other chronic obstructive pulmonary disease) plus those self-reported to have COPD: a total of 14,103 
(11,895 unrelated) cases. Using the broad definition of IPF, we subtracted 565 (482 unrelated) cases with both IPF and COPD to 
leave 13,538 (11,413 unrelated) cases.  




An IPF replication cohort was derived from the discovery stage of a recent GWAS study which comprised three independent 
case-control studies from the UK, Chicago and Colorado a total of 2,668 IPF cases and 8,591 controls 21. The UK study included 




The COPD replication cohort was derived from a recent COPD GWAS study with 15,256 cases and 47,936 controls, with 
13,710/15,256 (90%) of cases and 38,062/47,936 (79%) of controls being of European ancestry 22.   
 
IPF and COPD diagnoses were made in accordance with accepted international criteria. Both replication studies had appropriate 
international review board or ethics approval. 
 
Observational Associations 
We used logistic regression models in Stata 13.0 to compare the key demographics of the IPF and COPD groups with controls, 
adjusting for age and sex as appropriate. These analyses were performed in the unrelated subset of individuals to prevent 
familial bias. 
 
Identification of genetic instrument variants 
Genetic variants for telomere length were chosen from published GWAS studies, using GWAS that did not include data from 
the UK Biobank. We used an instrument composed of 7 variants robustly associated with LTL derived from a genome-wide 
meta-analysis of 37,684 individuals of European descent, with replication of selected variants in a further 10,739 individuals by 
Codd et al 14 (see Supplement p1). Other telomere length GWAS results were available (see 16) but with smaller sample sizes 
and several of the variants available were in linkage disequilibrium (Supplement p1) so did not meet our MR criteria.  
 
 
The extracted genetic variants, recoded to 0, 1 or 2 according to the number of telomere length associated alleles, were used 
to create a genetic risk score (GRS) for telomere length for each individual. The variants were weighted by their effect size (ß-
coefficient) obtained from the primary GWAS, where each beta value reflects the standard deviation change (1-SD) in LTL per 
copy of the effect allele:  
 
  Weighted score = ß1 x SNP1 + ß2 x SNP2 + …….. ßn x SNPn                    
 
Mendelian Randomisation 
Mendelian randomisation (MR) was used to investigate causality between telomere length and incidence of IPF and COPD. MR 
relies on several general assumptions 23 which are applied in this case as follows: 
a) the telomere length genetic variants are robustly associated with absolute LTL 
b) the telomere length genetic variants are not associated, independently of their effects on telomere length, with 
confounding variables for IPF or COPD 
c) the telomere length genetic variants are only associated with IPF or COPD via their effect on telomere length 
 
In this study, we employed several MR approaches. First, we investigated the association between IPF or COPD and the telomere 
length genetic risk scores in the unrelated data set of 379,708 individuals using logistic regression models. Ancestral principal 
components (as previously described 24) were included as covariates in the analysis to control for residual population structure 




We next performed two-sample MR using the BOLT-LMM (v2.3.4) algorithm for mixed model association testing. The seven 
genetic variants associated with telomere length were extracted. A standard Inverse Variance Weighted (IVW) instrumental 
variable analysis was performed in R (v3.5.2), along with two methods that are more resistant to pleiotropy: MR-Egger 25 and 
Median MR 26. The IVW method regresses the effect sizes of variant outcome associations (here telomere length associated 
variants vs incidence of IPF or COPD) against effect sizes of the variant risk factor associations (here telomere length associated 
variants vs telomere length). Variant risk factor associations were taken from the primary GWAS of telomere length 14. If no 
heterogeneity is detected amongst the causal estimates, the IVW analysis is carried out under a fixed effect model with the 
assumption of no horizontal pleiotropy. Alternatively, if heterogeneity is found amongst the causal estimates, a random effects 
model is implemented and the approach assumes that: 
a) Either the strength of the association of the genetic instruments with the risk factor is not correlated with the 
magnitude of the pleiotropic effects  
b) Or the pleiotropic effects have an average value of zero 
In contrast, the MR-Egger method uses a weighted regression with an unconstrained intercept to remove the assumption that 
all genetic variants are valid instrumental variables and is therefore less susceptible to confounding from potentially pleiotropic 
variants that have a stronger effect on the incidence of IPF compared to their effect on telomere length. The Median-MR 
method is also more resistant to pleiotropy; it takes the median instrumental variable from all variants included and is therefore 
robust when <50% of the genetic variants are invalid. Given these different assumptions, if all methods are broadly consistent 
this strengthens the causal inference. Details of the R code for the 2-sample IVW, MR-Egger and Median-MR analyses are 
available in Bowden et al 26,27. 
 
Two sample MR in our IPF and COPD replication cohorts used summary GWAS statistics, the majority of which excluded UK 
Biobank data (7,893/11,259=70% for IPF and 100% FOR COPD).  
 
Additional sensitivity analyses were performed to check the robustness of our results. First, the MR was repeated, excluding 
rs2736100 which has a reported link with IPF 28. Second, we repeated the regression analyses in the unrelated subset of 
individuals using sex specific genetic risk scores (see Supplement p2). Third, we checked sensitivity of regression analyses for 
COPD to case description, since the definition of COPD cases in our replication cohort was based on lung function data (FVC% 
predicted <80%, FEV1/FVC <0.7) rather than reported diagnosis and recent evidence has shown that a spirometric definition 
identifies more cases 29. Percent predicted spirometry values were generated in UK Biobank data using the Global Lung Initiative 
reference equations, for which the methodology used to derive the lower limit of normal (LLN) for all equations takes into 
account that the spread of values around the predicted values is not normal and depends on age and outcome 30. 
 
Role of the funding source 
The funding source had no involvement in: study design; collection, analysis, and interpretation of data; writing of the report; 
the decision to submit the paper for publication. AD, RNB, ARW, JT and CJS had access to the raw data. The corresponding 






The demographics of the unrelated 1,133 IPF ‘narrow’ cases and 11,413 COPD cases are summarised in Table 1 and 2. In general 
the odds ratios quoted for each exposure predict prevalence of IPF or COPD, but the mortality figures are the risk ratio for death 
with each disease. Strong associations were noted between IPF and a range of demographic and environmental variables. 
Briefly, older age, male sex, lower socioeconomic position, ever smoking, reduced lung function and reduced exercise were 
associated with a higher odds ratio for IPF and also for COPD. Similar associations were noted for the 1,353 IPF ‘broad’ cases 
and also in the larger cohort of related individuals (Supplement p3).  
 
Telomere length polygenic genetic risk score 
Using the 7-variant telomere length genetic risk score in our UK Biobank unrelated cohort, we demonstrated that the telomere 
length GRS was associated with higher odds of IPF in our ‘narrow’ definition group of 1,133 IPF cases; odds ratio ( OR) = 1.11 
[95%CI: 1.07-1.15], P = 2.1x10-8 (Figure 2). Repeating this for the broader definition IPF, containing 1,353 cases, did not greatly 
alter this finding, OR = 1.09 [95%CI: 1.05-1.13], P = 4.7x10-7 (Table 3).  
In contrast, no association was seen for our COPD group of 11,413 cases (OR 1.000 [95%CI: 0.99-1.01], P=0.98; Figure 2). 
With the 6 variant GRS (excluding rs2736100), the results were slightly attenuated but the GRS remained associated with IPF; 
for the ‘narrow’ group OR = 1.08 [95%CI: 1.04-1.13], P = 2.5x10-4 and for the broader definition IPF group OR = 1.06 [95%CI: 
1.02-1.10], P = 0.0027.  
Due to the strong association between IPF incidence and male sex (OR = 1.94 [95%CI: 1.71-2.19], P <1x10-15; Table 1), we used 
separate genetic risk scores for each sex, created from the 7 SNP sex specific beta values for telomere length. Repeating the 
MR generated similar results for males and females (Table 3).  
In our sensitivity studies, we repeated the analysis for COPD using a lung function definition and the results were very similar 
(Table 3). 
 
Two-sample MR analysis 
Two sample MR provided evidence that genetic predictors of telomere length are ssociated with the risk of IPF. From this, under 
untestable assumptions, we infer that shorter telomere length is a cause of IPF. In the UK Biobank, a genetically instrumented 
one standard deviation shorter telomere length was associated with higher odds of IPF; using the IVW method, in the narrow 
IPF group, OR = 4.19 [95% CI 2.33-7.55], P = 0.0031 and in the broad IPF group OR = 3.28 [95% CI 1.77-6.08], P = 0.0093. There 
was no evidence of a causal relationship in COPD (OR = 1.07 [95% CI 0.88-1.30], P = 0.51; Figures 3 & 4 and Supplement p5).  
For the IPF groups, all methods were directionally consistent and the Egger method provided no evidence of pleiotropy (Egger 
intercept P-value: 0.45 in IPF ‘narrow’ and 0.47 in IPF ‘broad’). There was no evidence of SNP heterogeneity for either cohort 
(Supplement p5) 
 
MR results from replication cohorts 
To provide further evidence for or against the causal role of telomere length in IPF, we used the summary statistics from the 
replication cohort data from 2,668 IPF patients and 8,591 controls. Again, two-sample MR provided evidence inferring a causal 
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role for shortened telomeres in IPF. A 1-SD decrease in telomere length was associated with OR = 12.3 [95% CI: 5.05-30.1], P = 
0.0015 (Figures 3 & 4 & Supplement p5). Similar associations were noted using the MR methods that are more robust to 
pleiotropy, and the Egger intercept provided no evidence of pleiotropy (P-value: 0.75).  
Results from the COPD replication cohort provided no evidence of a causal relationship in COPD (OR = 1.04 [95% CI 0.71-1.53], 
P = 0.83; Figures 3 & 4 and Supplement p5). 
There was some evidence of heterogeneity of the SNP effects (Supplement p5), with rs7675998 driving this heterogeneity in 
the IPF cohort. When the analysis was repeated without this SNP, the finding that short telomeres predict IPF remained. 
 
Meta-analysis of UK Biobank and replication cohort data 
Meta-analysis of the IVW model estimates for IPF from the UK Biobank and the replication cohort also inferred a causal 
relationship with a 1-SD shorter telomere length leading to OR= 5.81 [95% CI: 3.56-9.50], P= 2.19x10-12 for IPF. Using this model 
there is some evidence of heterogeneity between cohorts (heterogeneity P= 0.05). In comparison, meta-analysis of IVW 
estimates for COPD from the UK Biobank and the COPD replication cohort provided no evidence of any causal relationship for 
telomere length, with OR= 1.07 [95%CI:0.90-1.27, P=0.46, heterogeneity P=0.91]. Independent cohort and combined meta-
analysis results are shown in Figure 4.  
Similarly, meta-analysis results for MR-Egger estimates for IPF inferred a causal relationship for telomeres in IPF with a 1-SD 
shorter telomere length leading to OR= 15.8 [95% CI: 1.48-169], P= 0.022, with heterogeneity P= 0.80. Again, meta-analysis 
results using MR-Egger estimates for COPD provided no evidence of any causal relationship for telomere length, with OR= 1.07 





Using a Mendelian randomisation approach, we have shown that decreased telomere length is associated with increased risk 
of IPF but not COPD. The majority of our findings persisted when they were derived using models that made allowance for 
violations of MR assumptions, such as confounding by pleiotropy, with outcomes which were broadly consistent. An earlier 
study indicated that some genetic variants regulating telomere length are associated with risk of IPF and not COPD 16 and we 
further build on that assertion with data from larger cohorts than have been used previously, with a comprehensive and focused 
study, where we see a dose-dependent relationship in IPF across seven genetic predictors of telomere length. We also see little 
evidence of heterogeneity between variants in our cohorts. In the one instance where heterogeneity in the IPF replication 
cohort was apparent, this was driven by the single outlier SNP (rs7675998), which appears to have a different association with 
disease in UK and US cohorts. Taken together, these data therefore provide robust evidence inferring a causal link from short 
telomeres for idiopathic pulmonary fibrosis, while suggesting divergent underlying disease mechanisms in COPD. While COPD 
is not a reported association in families with telomere biology disorders 31, there are indications that short telomeres lower the 
threshold of chronic cigarette smoke-induced damage 32. Thus, although short telomeres do not appear to have a causal role in 





Both IPF and COPD are exemplars of age-related disease, with increasing focus on the impact of accelerated ageing and 
particularly the pathogenic role of cellular senescence (see 33 for a comprehensive review). This is a complex cellular programme 
and can be broadly subdivided into replicative and cellular senescence 34; the former results from intrinsic cellular events, 
including telomere shortening, while the latter can be driven by various stimuli including oxidative stress and DNA damage 35. 
IPF and COPD both have significantly shorter LTL 5,6; shortened telomeres have also been identified directly within lung tissue 
from IPF patients 8,36 but not in COPD 37. While there have been mixed reports on the direct correlation between leukocyte and 
tissue telomere length generally 37-39, the study by van Batenburg et al reported a significant positive correlation between LTL 
and lung biopsy telomere length in IPF (n=32, r=0.53, p=0.002) 8. In light of our findings, we speculate that telomere shortening 
could act as an intrinsic and systemic driving force of cellular senescence in IPF, akin to the relationship between telomere-
associated driver mutations in familial PF. In both diseases, short LTL could also result from immunosenescence, or possibly 
hypoxemia, given the reported association between telomere length and PaO2 40. Notably, LTL in COPD does not appear to be 
influenced by smoking status (current vs ex-smokers 41), although smoking per se can cause telomere attrition 42. Of interest, a 
recent study by Kachuri et al 43 used MR to investigate a causal role for longer telomeres in lung cancer, demonstrating an 
increased odds ratio for lung adenocarcinoma but not squamous cell carcinoma (SCC) or head and neck cancer. IPF is linked 
with an increased risk of lung cancer 44, but notably SCC rather than adenocarcinoma 45. 
 
Evidence inferring a causal role for premature telomere attrition in IPF does present several significant opportunities. 
Approaches aimed at addressing inadequate telomere maintenance either universally or in the cells contributing most to the 
disease pathogenesis, may offer a therapeutic option. Restoration of telomere length is not as straightforward as simply 
upregulating telomerase since this would promote the risk of cancers, although clinical trials are underway using this approach 
in other conditions (see NCT04110964 at clinicaltrials.gov). In light of this, safe telomerase activation therapy is being explored 
in other medical fields such as cardiology, using transient delivery which avoids creating an environment in which increased 
telomerase persists 46. Targeted delivery in vivo presents a very significant challenge to utilising such an approach in PF, but 
future developments may render this feasible. Diminution of the senescent cell burden in IPF is also currently being explored 
using senolytic drugs such as the combination of dasatinib plus quercetin, for which an open label Phase I Study has recently 
been reported 47. Alternative approaches could include exploration of androgen therapy: testosterone has been used effectively 
to treat the telomere linked disease, aplastic anaemia, for many years and Danazol has shown some promise in the treatment 
of PF, with an apparent arrest in lung function decline over 36 months 48. Androgens can also restore telomerase to normal 
levels in cells from telomere disease patients who are heterozygous for TERT gene mutations 49. 
 
There are also approaches which improve general wellbeing while also having a positive effect on promoting telomere length. 
We speculate these could be further promoted as an important part of clinical management of IPF patients, and include exercise 
50, reduction of life stress 51 and mindfulness 52,53. Our data show that participants with IPF tended to have reduced physical 
activity (Table 1), probably exaggerated by poor physical health; carefully increased exercise could offer multiple benefits in 
terms of promoting chromosomal telomere length and also boosting fitness and mental health. Similarly, stress arising from 
difficult life circumstances such as social deprivation (which our data show is associated with IPF, Table 1) can be relieved with 
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practices such as mindfulness 52,53. Relatively simply practices which improve patient wellbeing may also have a fundamentally 
positive impact on reducing telomere attrition. 
 
The most established genetic association with IPF to date has been a polymorphism (rs35705950) in the promoter of the MUC5B 
gene, and an inverse relationship between the presence of the risk allele and the presence of telomerase pathway rare variants 
has been reported 4. Although we had insufficient patient numbers to investigate this in the current study, stratification by 
MUC5B SNP status would be worthy of exploration in future work. 
 
Our study does have several limitations. While numbers of cases and controls in UK Biobank are large, those cases lack extensive 
clinical characterisation. This is mitigated to some extent by the thorough adjudicated diagnoses for cases in both our replication 
cohorts. Second, we have not assessed LTL directly since those data were not available for these cohorts. Instead, we have 
assumed that any systemic modifiers of telomere length will affect cells in which telomere length is actively maintained 
throughout life. This will include haematopoietic stem cells in the bone marrow from which leukocytes derive, but also type II 
alveolar epithelial cells, which are a focus of damage in the IPF lung. Our study does not therefore attempt to address the 
absolute extent to which telomere length in IPF is genetically or environmentally determined. Mendelian randomisation also 
has inherent limitations, in light of the three key assumptions described in the Methods. We have tested these assumptions 
using the different models described herein and, while the results were found to be broadly consistent, some residual 
uncertainty inevitably remains. This can be reduced further in future analyses with larger sample size, as and when these 
become available. 
 
To conclude, we have found evidence, in both our UK Biobank and replication cohorts, to infer a causal link between telomere 
length and sporadic IPF. We found no evidence of any link to COPD, a similar age-related disease, in either the UK Biobank or 
our COPD replication cohort. The inference of a cause behind human IPF leads us to new insights towards beneficial therapies 
for patients and routes to potential new treatments - which may lead us closer to preventing the disease in those with 
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Table 1: Demographics for idiopathic pulmonary fibrosis cases using narrow J84.1 ICD10 code definition, from 
unrelated individuals of European ancestry in UK Biobank derived using logistic regression analyses. Odds ratios 
show the extent to which the exposures predicted prevalence of IPF, except for ‘participants deceased’, which 
shows the risk ratio for death with IPF. (Odds ratios and p values are adjusted for age and sex, other than percent 
predicted spirometry which already includes adjustment). Income bands indicate average household income: 






Demographic IPF J84.1 
only 
Controls OR 95% CI P 
N = 368,075 1,133 366,942     
Mean age at baseline (SD) 
Mean age at diagnosis (SD) 
63.1 (5.8) 
67.2 (7.5) 
57.1 (8.0) 1.13 1.12 1.14 <1X10-15 
Male sex, N (%) 718 (63.4%) 167,910 (45.8%) 1.94 1.71 2.19 <1X10-15 
Townsend Deprivation Index (SD) -0.80 (3.33) -1.53 (2.95) 1.10 1.08 1.12 <1X10-15 
Pollution, NO2  μg/m3 (SD) 27.2 (8.0) 26.2 (7.4) 1.02 1.02 1.03 6.0x10-10 
Smoking status       
     Never smoker 341 (30.1%) 201,987 (55.1%)     
     Former smoker 602 (53.1%) 128,242 (35.0%) 2.14 1.87 2.45 <1X10-15 
     Current smoker 167 (14.7%) 32,022 (8.73%) 3.42 2.83 4.13 <1X10-15 
     Missing 23 (2.0%) 5,104 (1.3%)     
Median income band (IQR) 2 (1-3) 3 (2-4) 0.69 0.65 0.74 <1X10-15 
Mean FEV1 L (SD) 2.36 (0.69) 2.77 (0.77) 0.35 0.32 0.40 <1X10-15 
FEV1 percent predicted (SD) 85.0 (23.5) 91.1 (22.6) 0.99 0.98 0.99 <1X10-15 
Mean FVC L (SD) 3.18 (0.88) 3.66 (1.00) 0.42 0.38 0.46 <1X10-15 
FVC percent predicted (SD) 114.8 (29.6) 120.2 (29.6) 0.99 0.99 1.00 <1X10-15 
Physical activity score (SD) 7.07 (1.31) 7.41 (1.13) 0.76 0.73 0.81 <1X10-15 

























Table 2: Demographics for chronic obstructive pulmonary disease cases, from unrelated individuals of 
European ancestry in UK Biobank derived using logistic regression analyses Odds ratios show the extent to 
which the exposures predicted prevalence of COPD, except for ‘participants deceased’, which shows the risk 
ratio for death with COPD. (Odds ratios and p values are adjusted for age and sex, as above). Income bands 










Demographic COPD Controls OR 95% CI P 
N = 378,355 11,413 366,942     
Mean age at baseline (SD) 
Mean age at diagnosis (SD) 
61.9 (6.2) 
65.3 (7.4) 
57.1 (8.0) 1.10 1.09 1.10 <1X10-15 
Male sex, N (%) 6,245 (54.7%) 167,910 (45.8%) 1.38 1.32 1.43 <1X10-15 
Townsend Deprivation Index (SD) 0.21 (3.6) -1.53 (2.95) 1.19 1.19 1.20 <1X10-15 
Pollution  NO2  μg/m3 (SD) 28.0 (7.7) 26.2 (7.4) 1.04 1.03 1.04 <1X10-15 
Smoking status       
     Never smoker 1,806 (15.8%) 201,987 (55.1%)     
     Former smoker 5,480 (48.0%) 128,242 (35.0%) 3.96 3.75 4.18 <1X10-15 
     Current smoker 3,719 (32.6%) 32,022 (8.73%) 15.0 14.1 15.9 <1X10-15 
     Missing 408 (3.6%) 5,104 (1.3%)     
Median income band (IQR) 1 (1-2) 3 (2-4) 0.53 0.52 0.54 <1X10-15 
Mean FEV L (SD) 2.01 (0.72) 2.77 (0.77) 0.15 0.14 0.15 <1X10-15 
FEV1 percent predicted (SD) 71.2 (23.7) 91.1 (22.6) 0.96 0.96 0.96 <1X10-15 
Mean FVC L (SD) 3.04 (0.93) 3.66 (1.00) 0.34 0.33 0.35 <1X10-15 
FVC percent predicted (SD) 107.6 (30.4) 120.2 (29.6) 0.98 0.98 0.98 <1X10-15 
Physical activity score (SD) 7.12 (1.31) 7.41 (1.13) 0.80 0.79 0.81 <1X10-15 




Case Group Genetic instrument N cases (controls)  
Odds ratios (95%CI) for IPF 
vs control per SD change 
in LTL P 
IPF ‘narrow’ All 7 SNP 1,133 (366,942) 1.11 (1.07,1.15) 2.1x10-8 
IPF ‘narrow’ All 6 SNP - no rs2736100 1,133 (366,942) 1.08 (1.04, 1.13) 2.5x10-4 
IPF 'broad' All 7 SNP 1,353 (366,942) 1.09 (1.05, 1.13) 4.9x10-7 
IPF 'broad' All 6 SNP - no rs2736100 1,353 (366,942) 1.06 (1.02, 1.10)  2.7x10-3 
IPF ‘narrow’ Men only 7 SNP male grs 718 (174,254) 1.10 (1.05, 1.15) 2.4x10-5 
IPF ‘narrow’ Women only 7 SNP female grs 415 (204,321) 1.12 (1.05, 1.19) 2.2x10-4 
COPD (our definition) 7 SNP 11,413 (366,942) 1.000 (0.988, 1.012) 0.98 
COPD (our definition) 6 SNP 11,413 (366,942) 1.002 (0.989, 1.016) 0.71 
COPD (lung function definition) 7 SNP 30,359 (347,996) 1.003 (0.995, 1.010) 0.48 
 
Table 3: Evidence from UK Biobank data suggesting a causal role for telomere length in IPF but not in COPD. Associations 
between shorter telomere length genetic risk scores and disease incidence in IPF (‘narrow’), IPF (‘broad’), IPF males & IPF 
females (using the sex adjusted genetic risk scores) and COPD for genetic instruments derived from 7 and 6 variants. Results 













 Figure 1. Principle of Mendelian Randomisation; if telomere length plays a causal role in IPF or COPD, genetic variants 
associated with telomere length will also be associated with the disease. A) If the observed trait X causes the particular 
outcome Y, the instrument Z (genetic variants associated with the trait) will also be associated with the outcome. B) If telomere 
length causes idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD), the chosen genetic variants 
associated with telomere length will also be associated with IPF or COPD. As genotype is assigned at conception, it should not 
be associated with risk factors that might confound the association between telomere length and disease outcome (e.g. smoking 
or pollution). Weighted estimates of the genetic telomere length association (w) and the genetic disease association (x) are 






Figure 2. Logistic regression results showing significant disease risk odds ratio for IPF (‘narrow’) but not for COPD cases for a 
unit change in telomere length genetic risk score compared with controls in UK Biobank. An odds ratio of 1 shows that disease 
odds are not influenced by telomere length. An odds ratio significantly different to 1 indicates that odds of disease are 










Figure 3. Two-sample MR results for IPF and COPD showing evidence of telomere length causality in IPF but not in COPD.  
Graphs show the strength of the relationship between disease incidence and telomere length SNPs on the y axis against the 
telomere length association from previous GWAS for each SNP on the x axis. A non-zero gradient to the lines, with significant p 
values shown in the top left-hand box for the different MR models used, is evidence of causality of telomere length for disease. 
Results shown are for all seven telomere variants for (A) IPF (‘narrow’) in UK Biobank, (B) IPF Replication Cohort, (C) COPD in 





Figure 4. Meta-analysis results for IPF and COPD in UK Biobank and replication cohorts showing significant evidence of 
telomere length causality in IPF but not COPD across cohorts. Odds ratios and 95% confidence intervals are shown for a 
genetically-instrumented one standard deviation shorter telomere length in IPF (‘narrow’) in UKB, IPF Replication Cohort, IPF 
meta-analysis, COPD in UK Biobank, COPD Replication Cohort and COPD meta-analysis using IVW Method.  
 
